These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26126508)

  • 1. Lawsuit seeks access to data from hepatitis C drug trial.
    McCarthy M
    BMJ; 2015 Jun; 350():h3564. PubMed ID: 26126508
    [No Abstract]   [Full Text] [Related]  

  • 2. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 3. New Indications for Harvoni.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 5. Sofosbuvir (Sovaldi) for hepatitis C virus.
    Lomberk M; Klibanov OM
    Nurse Pract; 2015 Sep; 40(9):16-9. PubMed ID: 26274882
    [No Abstract]   [Full Text] [Related]  

  • 6. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 7. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
    Cuenca-Lopez F; Rivero A; Rivero-Juárez A
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):105-112. PubMed ID: 27797596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):572-5. PubMed ID: 26524329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payers consider waiting out budget-busting hepatitis C drug.
    Carroll J
    Manag Care; 2014 May; 23(5):7, 9. PubMed ID: 25016845
    [No Abstract]   [Full Text] [Related]  

  • 11. Take a Bow, Pharma, for the Hepatitis C Drugs.
    Reinke T
    Manag Care; 2018 Apr; 27(4):12-13. PubMed ID: 29701579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gilead injects own generics into shrinking HCV drug market.
    Morrison C
    Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
    [No Abstract]   [Full Text] [Related]  

  • 13. China rejects patent on hepatitis C drug sofosbuvir.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Mattingly Ii TJ; Heil EL; Hoke KS
    J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon free recovery for almost all patients].
    Einecke D
    MMW Fortschr Med; 2015 Mar; 157(4):71. PubMed ID: 25743991
    [No Abstract]   [Full Text] [Related]  

  • 16. Building bridges and providing transparency to the hepatitis C virus drug approval process.
    Ghany MG; Liang TJ
    Gastroenterology; 2014 Dec; 147(6):1201-3. PubMed ID: 25449025
    [No Abstract]   [Full Text] [Related]  

  • 17. Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
    Heppt F; Sticherling M
    Acta Derm Venereol; 2017 Apr; 97(4):526-527. PubMed ID: 27868140
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing a broader user base for new HCV drug.
    Sekkides O
    Lancet Infect Dis; 2015 Apr; 15(4):383. PubMed ID: 25809898
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Springer Medizin
    MMW Fortschr Med; 2016 Jul; 158(13):10-1. PubMed ID: 27439800
    [No Abstract]   [Full Text] [Related]  

  • 20. Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected.
    Herder M
    JAMA Intern Med; 2018 Aug; 178(8):1013-1014. PubMed ID: 29971404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.